Pharmaceutical developer Bristol-Myers Squibb Co., in Princeton, acquired San Diego-based Amylin Pharmaceuticals Inc., on Friday, for approximately $5.3 billion in cash to expand its research, development and commercialization of diabetes treatments.
Read More »